Health

Access Industries, Pfizer and SR One were among the investors in a $125m round for Nimbus Therapeutics while Aerwins agreed a reverse takeover.

Alphabet led a $1bn round for its Verily subsidiary while Kimco Realty and The Silverman Group were part of Gotham Greens’ $310m series E.

Corporates have dramatically slowed down the rate at which they invest in startups, except in these two sectors.

Investment is building again in the sector after a lull, but big companies are hedging their bets on which type of aircraft will work best.

Hitachi grows its cell therapy portfolio, SoftBank slims down in India and Foresight Williams backs ID tags for diamonds.

Hanwha Group took part in a $250m round for Carrot General Insurance while JP Morgan Chase helped lift LetsGetChecked’s series D to $170m.

Lab-grown milk is becoming commercially viable — and studies have shown that consumers aren’t averse to it. So, is it time for corporate investors to back these startups?

David Neustaedter, the 14-year corporate venturing veteran, has left his VP position at Medtronic and joined an undisclosed investment firm.

Reliance Egypt participated in Trukker’s $100m series C round while Merck, Eli Lilly and Heritage Medical all backed Photys’ $75m series A.

SoftBank, Bristol Myers Squibb and Hitachi were among Arsenal Biosciences’ $220m round while MegaChips led a $140m round for Morse Micro.

With three health corporate LPs in tow, Kortex Ventures’ focus is digital and personalised.